Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Reviva Pharmaceuticals Holdings, Inc. - Common Stock (NQ:RVPH)

1.120 +0.040 (+3.70%)
Streaming Delayed Price Updated: 3:05 PM EDT, Mar 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Reviva Pharmaceuticals Holdings, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Applied Therapeutics Appoints John H. Johnson as Executive Chairman
From Applied Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Mitek Systems Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst
The FDA's approval of Bristol Myers Squibb's Cobenfy for schizophrenia opens doors for Reviva's brilaroxazine, a multi-receptor antipsychotic. 
Via Benzinga
Exposures Product Safety
RVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q2 2024
RVPH stock results show that Reviva Pharmaceuticals beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
Exposures Legal Regulatory
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH
WHY: NEW YORK, NY - (NewMediaWire) - May 16, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Reviva... 
Via TheNewswire.com
Topics Regulatory Compliance
Exposures Legal Regulatory
RVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q1 2024
RVPH stock results show that Reviva Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPH
From The Rosen Law Firm PA
Via GlobeNewswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
Exposures Legal Regulatory
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH
WHY: NEW YORK, NY - (NewMediaWire) - May 13, 2024 - Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Reviva... 
Via TheNewswire.com
Topics Regulatory Compliance
Exposures Legal Regulatory
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
RVPH LOSS ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPH
From The Rosen Law Firm, P.A.
Via Business Wire
REVIVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Reviva Pharmaceuticals Holdings, Inc. on Behalf of Reviva Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
RVPH Stock Earnings: Reviva Pharmaceuticals Misses EPS for Q4 2023
RVPH stock results show that Reviva Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
These three companies are developing treatments for brain diseases that have a great deal of potential, making them top neuroscience stocks. 
Via InvestorPlace
Reviva to Present at Webull LIVE! Healthcare Webinar on January 17
Via ACCESSWIRE
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Life Science Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Life Science Investor Forum Agenda Announced for December 14th, 2023
From Virtual Investor Conferences
Via GlobeNewswire
Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum
From Virtual Investor Conferences
Via GlobeNewswire
Analyst Assessment On Reviva Pharmaceuticals' Positive Schizophrenia Trial Data - Sees More Than 200% Upside In Stock
Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) shares are surging after the company released topline results of its pivotal Phase 3 RECOVER trial evaluating brilaroxazine, a serotonin-dopamine... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Could This Be A Breakthrough in Mental Health? Reviva's Schizophrenia Drug Shows Promising Results In Key Trial
Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) announced the topline results of its pivotal Phase 3 RECOVER trial evaluating brilaroxazine, a serotonin-dopamine signaling modulator in  
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
Via ACCESSWIRE
Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
Via ACCESSWIRE
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.